Odontoprev S.A. Logo

Odontoprev S.A.

ODPV3.SA

(3.5)
Stock Price

11,34 BRL

35.35% ROA

50.74% ROE

11.39x PER

Market Cap.

6.152.294.148,00 BRL

2.2% DER

7.81% Yield

23.67% NPM

Odontoprev S.A. Stock Analysis

Odontoprev S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Odontoprev S.A. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (36.49%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a minimal amount of debt (2%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Net Profit Growth

The net profit of this company has steadily increased over the last five years, showcasing a favorable financial performance and making it an enticing option for investors seeking growth potential.

5 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

6 Dividend

With a solid track record of dividend payments over the past five years, the company has established itself as a dependable choice for investors seeking consistent income.

7 Revenue Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

8 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (73) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

9 PBV

The stock's elevated P/BV ratio (4.63x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

10 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

11 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Odontoprev S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Odontoprev S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Odontoprev S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Odontoprev S.A. Revenue
Year Revenue Growth
2003 94.374.991
2004 240.759.843 60.8%
2005 147.819.000 -62.87%
2006 188.796.000 21.7%
2007 259.108.000 27.14%
2008 318.205.000 18.57%
2009 379.454.000 16.14%
2010 697.787.000 45.62%
2011 835.263.000 16.46%
2012 955.483.000 12.58%
2013 1.069.606.000 10.67%
2014 1.156.121.000 7.48%
2015 1.249.691.000 7.49%
2016 1.365.039.000 8.45%
2017 1.437.283.000 5.03%
2018 1.594.874.000 9.88%
2019 1.808.926.000 11.83%
2020 1.765.338.000 -2.47%
2021 1.846.736.000 4.41%
2022 1.905.057.000 3.06%
2023 2.207.840.000 13.71%
2023 2.118.667.000 -4.21%
2024 2.281.176.000 7.12%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Odontoprev S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Odontoprev S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2003 24.229.425
2004 30.921.160 21.64%
2005 35.197.000 12.15%
2006 56.931.000 38.18%
2007 69.624.000 18.23%
2008 79.672.000 12.61%
2009 91.958.000 13.36%
2010 140.627.000 34.61%
2011 141.242.000 0.44%
2012 5.126.000 -2655.4%
2013 5.048.000 -1.55%
2014 6.233.000 19.01%
2015 11.649.000 46.49%
2016 2.891.000 -302.94%
2017 6.673.000 56.68%
2018 17.541.000 61.96%
2019 57.716.000 69.61%
2020 49.585.000 -16.4%
2021 46.100.000 -7.56%
2022 15.285.000 -201.6%
2023 63.980.000 76.11%
2023 55.441.000 -15.4%
2024 98.800.000 43.89%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Odontoprev S.A. EBITDA
Year EBITDA Growth
2003 33.400.775
2004 48.624.354 31.31%
2005 61.606.000 21.07%
2006 81.054.000 23.99%
2007 118.854.000 31.8%
2008 60.151.000 -97.59%
2009 93.089.000 35.38%
2010 184.336.000 49.5%
2011 252.079.000 26.87%
2012 250.964.000 -0.44%
2013 313.348.000 19.91%
2014 327.753.000 4.4%
2015 372.799.000 12.08%
2016 287.858.000 -29.51%
2017 581.641.000 50.51%
2018 363.907.000 -59.83%
2019 408.446.000 10.9%
2020 536.177.000 23.82%
2021 563.852.000 4.91%
2022 614.048.000 8.17%
2023 805.424.000 23.76%
2023 858.131.000 6.14%
2024 926.640.000 7.39%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Odontoprev S.A. Gross Profit
Year Gross Profit Growth
2003 48.814.407
2004 190.515.794 74.38%
2005 89.136.000 -113.74%
2006 120.880.000 26.26%
2007 169.373.000 28.63%
2008 200.193.000 15.4%
2009 234.766.000 14.73%
2010 352.656.000 33.43%
2011 418.799.000 15.79%
2012 469.955.000 10.89%
2013 568.441.000 17.33%
2014 607.284.000 6.4%
2015 667.163.000 8.98%
2016 693.235.000 3.76%
2017 1.042.123.000 33.48%
2018 833.597.000 -25.02%
2019 998.561.000 16.52%
2020 1.052.195.000 5.1%
2021 1.066.339.000 1.33%
2022 1.124.663.000 5.19%
2023 673.912.000 -66.89%
2023 864.533.000 22.05%
2024 981.112.000 11.88%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Odontoprev S.A. Net Profit
Year Net Profit Growth
2003 6.471.935
2004 12.022.927 46.17%
2005 17.755.000 32.28%
2006 16.911.000 -4.99%
2007 47.578.000 64.46%
2008 55.153.000 13.73%
2009 59.128.000 6.72%
2010 219.427.000 73.05%
2011 145.670.000 -50.63%
2012 145.566.000 -0.07%
2013 188.091.000 22.61%
2014 194.709.000 3.4%
2015 220.946.000 11.87%
2016 215.990.000 -2.29%
2017 502.919.000 57.05%
2018 284.793.000 -76.59%
2019 284.763.000 -0.01%
2020 361.128.000 21.15%
2021 380.359.000 5.06%
2022 365.860.000 -3.96%
2023 536.924.000 31.86%
2023 511.394.000 -4.99%
2024 520.540.000 1.76%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Odontoprev S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 1 0%
2018 0 0%
2019 0 0%
2020 1 0%
2021 1 0%
2022 1 0%
2023 1 0%
2023 1 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Odontoprev S.A. Free Cashflow
Year Free Cashflow Growth
2005 22.495.000
2006 12.661.000 -77.67%
2007 55.957.000 77.37%
2008 64.047.000 12.63%
2009 67.606.000 5.26%
2010 539.301.000 87.46%
2011 117.827.000 -357.71%
2012 213.207.000 44.74%
2013 205.830.000 -3.58%
2014 261.892.000 21.41%
2015 223.191.000 -17.34%
2016 182.760.000 -22.12%
2017 275.613.000 33.69%
2018 302.259.000 8.82%
2019 276.011.000 -9.51%
2020 270.007.000 -2.22%
2021 811.938.000 66.75%
2022 631.591.000 -28.55%
2023 137.369.000 -359.78%
2023 327.805.000 58.09%
2024 85.963.000 -281.33%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Odontoprev S.A. Operating Cashflow
Year Operating Cashflow Growth
2005 23.854.000
2006 17.152.000 -39.07%
2007 57.582.000 70.21%
2008 65.441.000 12.01%
2009 69.711.000 6.13%
2010 547.531.000 87.27%
2011 124.780.000 -338.8%
2012 223.789.000 44.24%
2013 216.690.000 -3.28%
2014 280.396.000 22.72%
2015 237.090.000 -18.27%
2016 196.299.000 -20.78%
2017 289.483.000 32.19%
2018 324.197.000 10.71%
2019 308.794.000 -4.99%
2020 305.267.000 -1.16%
2021 858.423.000 64.44%
2022 694.581.000 -23.59%
2023 159.342.000 -335.91%
2023 423.058.000 62.34%
2024 106.661.000 -296.64%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Odontoprev S.A. Capital Expenditure
Year Capital Expenditure Growth
2005 1.359.000
2006 4.491.000 69.74%
2007 1.625.000 -176.37%
2008 1.394.000 -16.57%
2009 2.105.000 33.78%
2010 8.230.000 74.42%
2011 6.953.000 -18.37%
2012 10.582.000 34.29%
2013 10.860.000 2.56%
2014 18.504.000 41.31%
2015 13.899.000 -33.13%
2016 13.539.000 -2.66%
2017 13.870.000 2.39%
2018 21.938.000 36.78%
2019 32.783.000 33.08%
2020 35.260.000 7.02%
2021 46.485.000 24.15%
2022 62.990.000 26.2%
2023 21.973.000 -186.67%
2023 95.253.000 76.93%
2024 20.698.000 -360.2%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Odontoprev S.A. Equity
Year Equity Growth
2003 14.206.063
2004 21.282.173 33.25%
2005 10.341.000 -105.8%
2006 196.218.000 94.73%
2007 227.499.000 13.75%
2008 244.414.000 6.92%
2009 780.685.000 68.69%
2010 719.458.000 -8.51%
2011 764.040.000 5.84%
2012 701.301.000 -8.95%
2013 697.802.000 -0.5%
2014 644.248.000 -8.31%
2015 653.791.000 1.46%
2016 697.709.000 6.29%
2017 926.609.000 24.7%
2018 1.031.688.000 10.19%
2019 1.116.493.000 7.6%
2020 1.206.585.000 7.47%
2021 1.121.249.000 -7.61%
2022 1.185.518.000 5.42%
2023 38.309.000 -2994.62%
2023 1.387.674.000 97.24%
2024 1.235.303.000 -12.33%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Odontoprev S.A. Assets
Year Assets Growth
2003 36.690.795
2004 49.303.328 25.58%
2005 48.210.000 -2.27%
2006 244.086.000 80.25%
2007 306.139.000 20.27%
2008 339.047.000 9.71%
2009 1.140.630.000 70.28%
2010 912.963.000 -24.94%
2011 993.258.000 8.08%
2012 998.701.000 0.55%
2013 1.073.885.000 7%
2014 1.102.673.000 2.61%
2015 1.195.650.000 7.78%
2016 1.358.010.000 11.96%
2017 1.389.568.000 2.27%
2018 1.647.584.000 15.66%
2019 1.768.742.000 6.85%
2020 1.921.049.000 7.93%
2021 1.933.841.000 0.66%
2022 2.019.853.000 4.26%
2023 2.159.402.000 6.46%
2023 2.163.973.000 0.21%
2024 2.375.069.000 8.89%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Odontoprev S.A. Liabilities
Year Liabilities Growth
2003 22.484.732
2004 28.021.155 19.76%
2005 37.869.000 26.01%
2006 47.868.000 20.89%
2007 78.640.000 39.13%
2008 94.633.000 16.9%
2009 359.945.000 73.71%
2010 193.505.000 -86.01%
2011 229.218.000 15.58%
2012 297.400.000 22.93%
2013 376.083.000 20.92%
2014 458.425.000 17.96%
2015 541.859.000 15.4%
2016 660.301.000 17.94%
2017 462.959.000 -42.63%
2018 615.896.000 24.83%
2019 652.249.000 5.57%
2020 714.464.000 8.71%
2021 812.592.000 12.08%
2022 834.335.000 2.61%
2023 2.121.093.000 60.66%
2023 776.299.000 -173.23%
2024 1.139.766.000 31.89%

Odontoprev S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
4.05
Net Income per Share
0.96
Price to Earning Ratio
11.39x
Price To Sales Ratio
2.77x
POCF Ratio
13.5
PFCF Ratio
16.98
Price to Book Ratio
4.85
EV to Sales
2.78
EV Over EBITDA
6.9
EV to Operating CashFlow
13.91
EV to FreeCashFlow
17.02
Earnings Yield
0.09
FreeCashFlow Yield
0.06
Market Cap
6,15 Bil.
Enterprise Value
6,17 Bil.
Graham Number
6.97
Graham NetNet
-0.67

Income Statement Metrics

Net Income per Share
0.96
Income Quality
0.84
ROE
0.51
Return On Assets
0.22
Return On Capital Employed
0.46
Net Income per EBT
0.71
EBT Per Ebit
1.18
Ebit per Revenue
0.28
Effective Tax Rate
0.29

Margins

Sales, General, & Administrative to Revenue
0.03
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.38
Operating Profit Margin
0.28
Pretax Profit Margin
0.33
Net Profit Margin
0.24

Dividends

Dividend Yield
0.08
Dividend Yield %
7.81
Payout Ratio
0.42
Dividend Per Share
0.85

Operating Metrics

Operating Cashflow per Share
0.81
Free CashFlow per Share
0.66
Capex to Operating CashFlow
0.18
Capex to Revenue
0.04
Capex to Depreciation
1.37
Return on Invested Capital
0.35
Return on Tangible Assets
0.35
Days Sales Outstanding
15.93
Days Payables Outstanding
6.9
Days of Inventory on Hand
0.01
Receivables Turnover
22.92
Payables Turnover
52.9
Inventory Turnover
55312.8
Capex per Share
0.15

Balance Sheet

Cash per Share
1,28
Book Value per Share
2,25
Tangible Book Value per Share
0.63
Shareholders Equity per Share
2.25
Interest Debt per Share
0.13
Debt to Equity
0.02
Debt to Assets
0.01
Net Debt to EBITDA
0.02
Current Ratio
0.79
Tangible Asset Value
0,35 Bil.
Net Current Asset Value
-0,33 Bil.
Invested Capital
732771000
Working Capital
-0,21 Bil.
Intangibles to Total Assets
0.37
Average Receivables
0,10 Bil.
Average Payables
0,02 Bil.
Average Inventory
13000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Odontoprev S.A. Dividends
Year Dividends Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 1 0%

Odontoprev S.A. Profile

About Odontoprev S.A.

Odontoprev S.A. provides private dental plans in Brazil and internationally. The company operates through Corporate, Small and Medium-Enterprise, Individual, and Other segments. It manages and sells dental care plans to corporations and/or individuals; provides commercial advisory, consulting, and business management services; and develops and licenses software programs. The company also retails and wholesales dental equipment and products, sanitizers, drugs, medicines, pharmaceutical inputs, and related items; offers warehousing, storage, loading, organization, custody of goods, technical, and administrative programming services, as well as general management of goods and business; and provides services of collecting, sending or delivering mail, documents, and objects or goods. In addition, it offers services related to accidents, diseases, and health insurance; and financial, and commercial and risk management services. The company was founded in 1987 and is headquartered in Barueri, Brazil. Odontoprev S.A. is a subsidiary of Bradesco Saúde S.A.

CEO
Mr. Elsen Carvalho
Employee
1.947
Address
Alameda Araguaia, 2104
Barueri, 06455-000

Odontoprev S.A. Executives & BODs

Odontoprev S.A. Executives & BODs
# Name Age
1 Mr. Elsen Carvalho
Chief Executive Officer & Commercial Director
70
2 Ms. Stella Hong
IR Supervisor
70
3 Ms. Rose Gabay
Human Resources Director
70
4 Mr. André Chidichimo de França
Legal, Compliance Officer, DPO & Corporate Governance Officer
70
5 Mr. Renato Alves Costa Velloso Dias Cardoso
IT, Marketing & Sustainability Director
70
6 Mr. José Roberto Borges Pacheco
Investor Relations Officer & Chief Financial Officer
70

Odontoprev S.A. Competitors

Porto Seguro S.A. Logo
Porto Seguro S.A.

PSSA3.SA

(3.5)
Fleury S.A. Logo
Fleury S.A.

FLRY3.SA

(2.8)
Grendene S.A. Logo
Grendene S.A.

GRND3.SA

(2.5)
Hypera S.A. Logo
Hypera S.A.

HYPE3.SA

(3.8)